Clinical Trials Logo

Filter by:
NCT ID: NCT05429632 Recruiting - Clinical trials for Adult Acute Myeloid Leukemia

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

MO-TRANS
Start date: June 16, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blinded, placebo controlled trial.

NCT ID: NCT05428579 Completed - Clinical trials for Surgical Procedure, Unspecified

Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma

Start date: October 1, 2017
Phase:
Study type: Observational

Soft tissue sarcomas are rare malignant tumors. Liposarcoma constitute the most frequent histological subtype of retroperitoneal sarcoma. The prognosis of soft tissue sarcomas depend on clinical and histologic characteristics. Objective: Evaluate variables that may be related to overall survival and local recurrence free survival in patients with retroperitoneal liposarcoma. Methods: retrospective analysis of medical records of 60 patients attended from 1997 to 2017, who underwent surgical resection of retroperitoneal liposarcoma.

NCT ID: NCT05427370 Recruiting - Clinical trials for Coronary Artery Disease

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

Start date: June 22, 2023
Phase: N/A
Study type: Interventional

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.

NCT ID: NCT05427097 Completed - Dizziness Clinical Trials

Thermal Energy in the Treatment of Cervicogenic Dizziness

Start date: September 26, 2018
Phase: N/A
Study type: Interventional

Cervical pain contributes to postural deviations and imbalance. Nanotechnology may be used for the treatment of neck pain by fixing to the skin small rounds silicone patches containing double spiral carbon nanotubes arranged in the form of a coil (Helical), which would then relieve dizziness caused by muscular contraction.

NCT ID: NCT05423327 Terminated - Clinical trials for Non-alcoholic Steatohepatitis (NASH)

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Start date: December 9, 2021
Phase: N/A
Study type: Interventional

Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)

NCT ID: NCT05422547 Recruiting - Clinical trials for Colon Adenocarcinoma

Role of Immunoscore® in Stage II-III Colorectal Cancer

Start date: April 1, 2022
Phase:
Study type: Observational

The proposed study is a bidirectional analytical study, composed of a retrospective and a prospective cohorts. Patients with stage II - III colorectal cancer undergoing oncological surgery will be analyzed. The study will include a convenience sample of 100 individuals. Fifty cases will be included retrospectively and fifty prospectively. The study aims to evaluate the benefit of using the Immunoscore test as a predictor of recurrence in patients with operated stage II-III colon tumors. It will also be evaluated the impact on oncologic decision and costs.

NCT ID: NCT05421598 Active, not recruiting - Asthma Clinical Trials

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

TIDE-asthma
Start date: June 30, 2022
Phase: Phase 2
Study type: Interventional

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma. Study details include: - The study duration (per participant) will be up to approximately 76 weeks for participants not going into LTS study and will be up to approximately 64 weeks for participants going into LTS study. - The randomized treatment duration will be up to approximately 60 weeks. - The scheduled number of visits will be 13.

NCT ID: NCT05421533 Recruiting - Atrial Fibrillation Clinical Trials

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

GARDENIA
Start date: September 14, 2022
Phase:
Study type: Observational [Patient Registry]

The GARDENIA registry will collect real-world clinical data on the anticoagulant strategies in patients with AF at elevated risk of stroke but also elevated risk of bleeding.

NCT ID: NCT05419388 Recruiting - Melanoma Clinical Trials

A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Start date: August 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for further development.

NCT ID: NCT05419375 Recruiting - Solid Tumors Clinical Trials

Screening Study for Participants With Malignant Tumors

Start date: July 22, 2022
Phase: Phase 2
Study type: Interventional

The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.